Comparison of the effects of Topiramate and Gabapentin in Opioid withdrawal syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210427051102N1

Enrollment

Registered

2021-05-16

Start date

2021-06-22

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid Withdrawal syndrome. Opioid dependence with withdrawal

Interventions

Intervention 1: Patients in the first group take 300-1200mg of oral Gabapentin daily from Poursina company for one to a maximum of three weeks. Intervention 2: Patients in the second group take 100-30

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Detection of opioid dependence according to DSM-V criteria

Exclusion criteria

Exclusion criteria: Major medical diseases including cardiovascular, pulmonary, renal and gastrointestinal disorders Pregnancy and Lactation period

Design outcomes

Primary

Measure	Time frame
The score of Opioid Withdrawal Syndrome in the Questionnaire. Timepoint: Before intervention and 3, 5, 7, 9 and 11 days after starting gabapentin or topiramate. Method of measurement: Subjective Opiate Withdrawal Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParmida Rajabi

Fasa University of Medical Sciences

p.rajabi75@gmail.com+98 71 5333 2326

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026